Zhdan V. M., Tkachenko M. V., Babanina M. Yu., Volchenko G. V., Kitura Ye. M., Kyrian O. A.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

Gout is one of the most common inflammatory diseases of the joints, which is often accompanied by comorbid pathology, most often diseases of the cardiovascular system and metabolic disorders. This fact reflects the influence of hyperuricemia and the lack of compensation for purine metabolism disorders. Most researchers explain the lack of effective control of purine metabolism in gout with patients’ low adherence to treatment. This idea led to the formation of the concept of insufficient use of hypouricemic therapy and, as a result, to the lack of control over the course of the disease and the possibility of preventing the deterioration of the general state of the patient’s health, which is largely due to the progression of concomitant pathology. Many retrospective studies demonstrate a low frequency of timely appointment of hypouricemic therapy, inefficient dosage, which does not allow to reach target levels of SC in blood serum and effectively control the disease. Febuxostat is an effective means of reducing the level of SC in the blood serum in this disease. The literature provides data on the serious advantages of febuxostat over other hypouricemic agents. The purpose of this work was to study the possibility of obtaining a clinical and laboratory effect in a short time after the start of febuxostat therapy (up to 3 months) in patients with gouty nephropathy who have concomitant pathology. A study of the efficacy and safety of febuxostat (tablets of 80 or 120 mg) was conducted in gout patients with concomitant diseases. The observation period was 3 months, during which time the possibility of patients achieving the target level of SC (≤360 μmol/l) was evaluated. 6 patients reached the target SC level within 1.5 months of treatment. In 19 (30%) patients, the SC level decreased to ≤360 μmol/L after 3 months of therapy. Exacerbations of gout were noted in the first 2 months of therapy in individual patients and were characterized by less activity of joint syndrome. It is known that hyperuricemia is one of the main risk factors for endothelial dysfunction, which, in turn, contributes to the development of arterial hypertension and damage to target organs. Regardless of hypertension, an increase in the level of SC in the blood serum affects the cells of the endothelium and vascular smooth muscle, leading to the formation of microvascular damage to the kidneys. According to our data, the presence of CKD, DM and/or hypertension significantly reduces the speed of reaching the target levels of SC and increases the frequency of new cases of gout attacks, each of which increases the severity of inflammation, as well as the risk of cardiovascular disasters and death. Achieving the target level of SC in 6 patients 1.5 months after starting febuxostat and in a quarter of patients after 3 months. therapy demonstrates its powerful hypouricemic effect, which provides an early response to treatment.

: febuxostat,gouty nephropathy,comorbidity.

1. Roddy E, Zhang W, Doherty M. Is gout associated with reduced quality of life? A casecontrol study. Rheumatology (Oxford). 2007 Sep;46(9):1441-4. DOI: 10.1093/rheumatology/kem150.
2. Singh JA, Strand V. Gout is associated with more comorbidities, poorer healthrelated quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis. 2008 Sep;67(9):1310-6. DOI: 10.1136/ard.2007.081604.
3. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol. 2004 Aug;31(8):1582-7.
4. Miao Z, Li C, Chen Y, Zhao S, Wang Y, Wang Z, et al. Dietary and lifestyle changes associated with high prevalence of hyperuricaemia and gout in the Shandong coastal cities of Eastern China. J Rheumatol. 2008 Sep;35(9):1859-64.
5. Zhdan VM, Kitura OYe, Kitura YeM, Babanina MYu, Tkachenko MV Hyperuricemia and arterial hypertension in general practice. Materialy mezhdunar. nauch.-prakt. konf. Akademicheskaya nauka – problemy i dostizheniya; 2014 Dec 1-2; North Charleston, USA; 2014;3:46-49. [in Ukrainian]
6. Primatesta P, Plana E, Rothenbacher D. Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population. BMC Musculoskelet Disord. 2011 May 20;12:103. DOI: 10.1186/1471- 2474-12-103.
7. Brucato A, Cianci F, Carnovale C. Management of hyperuricemia in asymptomatic pa tients: a critical appraisal. Eur J Intern Med. 2020 Apr;74:8-17. DOI: 10.1016/j.ejim.2020.01.001.
8. Harrold LR, Mazor KM, Velten S, Ockene IS, Yood RA. Patients and providers view gout differently: a qualitative study. Chronic Illn. 2010 Dec;6(4):263-71. DOI: 10.1177/17423953 10378761.
9. Spencer K, Carr A, Doherty M. Patient and provider barriers to effective management of gout in general practice: a qualitative study. Ann Rheum Dis. 2012 Sep;71(9):1490-5. DOI: 10.1136/annrheumdis-2011-200801.
10. Jeyaruban A, Soden M, Larkins S. General practitioners’ perspectives on the management of gout: a qualitative study. Postgrad Med J. 2016 Oct;92(1092):603-7. DOI: 10.1136/postgradmedj-2015-133920.
11. Keenan RT. Limitations of the current standards of care for treating gout and crystal deposition in the primary care setting: a review. Clin Ther. 2017 Feb;39(2):430-41. DOI: 10.1016/ j.clinthera.2016.12.011.
12. Roddy E, Packham J, Obrenovic K, Rivett A, Ledingham JM. Management of gout by UK rheumatologists: a British Society for Rheumatology national audit. Rheumatology (Oxford). 2018 May 1;57(5):826-30. DOI: 10.1093/rheumatology/kex521.
13. Zhdan VM, Kitura OIe, Kitura YeM, Babanina MIu, Tkachenko MV. Hiperurykemiia i arterialna hipertenziia u zahalnolikarskii praktytsi. Simeina medytsyna. 2015;4(60):48-50. [in Ukrainian].
14. Tkachenko MV. Hipourykemichna terapiia dlia profilaktyky ta likuvannia podahry: aktualnyi stan problemy. Svit medytsyny ta biolohii. 2017;4(62):197-203. [in Ukrainian].
15. WHO. International Obesity Task Force. Managing the Global Epidemic of Obesity. Report of the World Health Organization (WHO) Consultation on Obesity; June 5-7. Geneva: WHO; 1997.
16. Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol. 2005 Dec;16(12):3553-62. DOI: 10.1681/ASN.2005050572.
17. Kang DH, Han L, Ouyang X, Kahn AM, Kanellis J, Li P, et al. Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. Am J Nephrol. Sep-Oct 2005;25(5):425-33. DOI: 10.1159/000087713.
18. Feig DI, Nakagawa T, Karumanchi SA, Oliver WJ, Kang D-H, Finch J, et al. Hypothesis: Uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney Int. 2004 Jul;66(1):281-7. DOI: 10.1111/j.1523-1755.2004.00729.x.
19. Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017 Jan;76(1):29-42. DOI: 10.1136/annrheumdis-2016-209707.
20. Zhdan VM, Shylkina LM, Babanina MIu, Kitura YeM, Tkachenko MV, Kyrian OA, et al. Multydystsyplinarnyi pidkhid do diahnostyky hiperurykemichnoho syndromu yak proiavu polimorbidnoi patolohii v praktytsi simeinoho likaria. Materialy Vseukr. nauk.-prak. konf. Profilaktyka, diahnostyka i likuvannia v praktytsi simeinoho likaria; 2016 Kvit 20-21; Kharkiv. Kharkiv: Skhidnoievropeiskyi zhurnal vnutrishnoi ta simeinoi medytsyny; 2016;1:10-11. [in Ukrainian].
21. Fuldeore MJ, Riedel AA, Zarotsky V, Pandya BJ, Dabbous O, Krishnan E. Chronic kidney disease in gout in a managed care setting. BMC Nephrol. 2011 Aug 3;12:36. DOI: 10.1186/1471-2369-12-36.
22. Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006 Aug;33(8):1646-50.
23. Zhdan VM, Tkachenko MV, Babanina MIu, Volchenko HV, Kitura YeM. Otsinka vplyvu alopurynolu na funktsiiu nyro. Svit medytsyny ta biolohii. 2019;1(67):51-55. [in Ukrainian].
24. Schumacher HR, Becker MA, Lloyd E, MacDonald PA, Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009 Feb;48(2): 188-94. DOI: 10.1093/rheumatology/ken457.
25. Hisatome I, Li P, Miake M, Taufiq F, Mahati E, Maharani N, et al. Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease. Japanese Guideline on the Management of Asympto matic Hyperuricemia. Circ J. 2021 Jan 25; 85(2):130-8. DOI: 10.1253/circj. CJ-20-0406.
26. Bubb MR. Excess deaths upon cessation of xanthine oxidase inhibitor treatment-Data from the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities trial: Comment on the Article by Choi et al. Arthritis Rheumatol. 2019 Aug;71(8):1391-2. DOI: 10.1002/art.40914.
27. Johnson TA, Kamatani N, Kuwabara M. Xanthine oxidase inhibitor withdrawal syndrome? Comment on the Article by Choi et al. Arthritis Rheumatol. 2019 Nov;71(11):1966-7. DOI: 10.1002/art.41066.
28. Prins KW, Neill JM, Tyler JO, Eckman PM, Duval S. Effects of beta-blocker withdrawal in acute decompensated heart failure: A systematic review and meta-analysis. JACC Heart Fail. 2015 Aug;3(8):647-53. DOI: 10.1016/j.jchf.2015. 03.008.
29. MacDonald TM, Ford I, Nuki G, Mackenzie IS, De Caterina R, Findlay E, et al. Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): A large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia. BMJ Open. 2014 Jul 10;4(7):e005354. DOI: 10.1136/ bmjopen-2014-005354.
30. Cicero AFG, Fogacci F, Cincione RI, Tocci G, Borghi C. Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients. Med Princ Pract. 2021;30(2):122-30. DOI: 10.1159/ 000512178.
31. Scire СA, Carrara G, Viroli C, Cimmino MA, Taylor WJ, Manara M, et al. Development and First Validation of a Disease Activity Score for Gout. Arthritis Care Res (Hoboken). 2016 Oct;68(10):1530-7. DOI: 10.1002/acr.22844.
32. Bao H, Qi Y, Wei B, Ma B, Wang Y, Xu Y. Severe erosive lesion of the glenoid in gouty shoulder arthritis: a case report and review of the literature. BMC Musculoskelet Disord. 2021 Apr 12;22(1):343. DOI: 10.1186/s12891-021-04217-5.
33. Meng J, Li Y, Yuan X, Lu Y. Effect of febuxostat on insulin resistance and expression of highly sensitive C-reactive protein in patients with primary gout. Rheumatol Int. 2017 Feb;37(2):299-303. DOI: 10.1007/s00296-016- 3612-2.
34. Cicero AFG, Fogacci F, Kuwabara M, Borghi C. Therapeutic strategies for the treatment of chronic hyperuricemia: an evidencebased update. Medicina (Kaunas). 2021 Jan 10;57(1):58. DOI: 10.3390/medicina57010058.
35. Tayar JH, Lopez-Olivo MA, Suarez- Almazor ME. Febuxostat for the treatment of chronic gout. Cochrane Database Syst Rev. 2012 Nov 14;11(11):CD008653. DOI: 10.1002/14651858.CD008653.pub2.

«Bulletin of problems biology and medicine» Issue 3 (166), 2022 year, 194-205 pages, index UDK 616.72-002.78-085

10.29254/2077-4214-2022-3-166-194-205